CytomX Therapeutics, Inc. — Revenue by Fiscal Year
13 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/dc5d13e7-3923-4713-88c0-a80148751b73/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $76.2M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-107146 |
| FY 2024 | $138.1M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-034575 |
| FY 2023 | $101.2M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-029191 |
| FY 2022 | $53.2M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-009991 |
| FY 2021 | $37.3M | 2021-01-01 – 2021-12-31 | evidence 0000950170-23-009984 |
| FY 2020 | $68.4M | 2020-01-01 – 2020-12-31 | evidence 0000950170-23-009984 |
| FY 2019 | $26.9M | 2019-01-01 – 2019-12-31 | evidence 0000950170-23-009984 |
| FY 2018 | $59.5M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-004890 |
| FY 2017 | $71.6M | 2017-01-01 – 2017-12-31 | evidence 0001564590-19-004890 |
| FY 2016 | $12.8M | 2016-01-01 – 2016-12-31 | evidence 0001564590-19-004890 |
| FY 2015 | $7.7M | 2015-01-01 – 2015-12-31 | evidence 0001564590-16-014091 |
| FY 2014 | $5.1M | 2014-01-01 – 2014-12-31 | evidence 0001564590-16-014091 |
| FY 2013 | $888.0k | 2013-01-01 – 2013-12-31 | evidence 0001564590-16-014091 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
CytomX Therapeutics, Inc. — all facts · Net Income · Operating Income